SEINE BIO · SCIENCE LIBRARY

IGF-1 DES

IGF-1 DES usually refers to des(1–3)IGF-I, a truncated IGF-I analogue.

Research compound

A closer look at the research, the uncertainties and the questions worth asking.

THE FULL READING GUIDE · UPDATED OCTOBER 7, 2026

Inside the science of IGF-1 DES.

Educational purpose only. Not medical advice. Consult licensed provider. Obtain from authorized compounding pharmacies only.

Compounding is an option only where the particular substance, product, and prescribing pathway are lawful; a pharmacy cannot make every research compound available for patient use. Approved finished medicines may also be obtained from licensed non-compounding pharmacies.

Overview

IGF-1 DES usually refers to des-(1–3)-IGF-1, a truncated insulin-like growth factor analog missing the first three amino acids. It is different from IGF-1 LR3 and the approved medicine mecasermin. Those distinctions affect study interpretation; shared growth-factor terminology does not make the products interchangeable.

Community Use

PeptideDosages.com describes DES as a research analog and discusses growth, binding proteins, and metabolic signaling. Performance claims should remain clearly separated from that research context. A narrative about local muscle effects is not a demonstrated human outcome, and no verified community claim is treated as a prescription here.

Doses, Durations & Cycles

Informal biohacking protocols and published regimens. Attributed website reports for education, not medical recommendations. Multiple publications document circulation; they do not establish a safe dose or validate a cycle.

Protocol reference — IGF-1 DES
Route / formulation	Dose / reported phases	Frequency	Duration / break	Notes and source
Subcutaneous in the main dosing section	50 mcg introductory amount; 75–100 mcg standard per session; separate high tier: 100–150 mcg	Once per training session, usually three to five sessions weekly	4–6 weeks Break: 4–6 weeks	Published informal biohacking claim Ki Researcher
Intramuscular	50 mcg	Training days, pre-workout; no weekly count stated	4 weeks Break: 4 weeks	Published informal biohacking claim AnyPeptides

Important context: DES(1–3) IGF-1 is the N-terminally truncated analog, not LR3 and not approved native mecasermin. Do not silently replace SC with IM, combine the tiers, or invent a frequency count/off-period for the third source.

Sources checked October 7, 2026. Educational listing does not establish prescribing approval or availability through Seine Bio.

No FDA-approved DES performance or recovery dose is established. A cell concentration or diabetic-rat exposure cannot be converted into a personal amount. The source chart is context rather than directions. Neither a pre-workout interval nor a localized-use schedule is established by the original study cited below.

Research Findings

A 1991 study evaluated IGF-related treatment in diabetic rats over a short experimental period, including nitrogen balance and muscle protein-synthesis outcomes. It was not a human athletic trial. Improvements in that disease model cannot establish selective muscle growth, improved recovery, or a dependable benefit in healthy people.

U.S. Approval & Access

IGF-1 DES is not FDA-approved. Mecasermin’s approved indication concerns a different preparation and defined pediatric patients. It does not authorize this truncated analog for a performance program. Lawful clinical availability needs a current product-specific pathway rather than a research-supplier listing or a similar molecule’s approval.

What It Does in the Body

Truncation can change interactions with binding proteins and receptor exposure. That is a pharmacology distinction, not proof that a brief exposure produces a lasting targeted benefit. Reliable route-specific human onset, peak concentration, and clinical duration are not established by the animal paper, and community timing claims cannot fill that gap.

Benefits & Reported Experiences

The measured rat outcomes are not equivalent to human strength, muscle size, or return to sport. An experiment in diabetes also has a different metabolic context from healthy-person use. Claims should state the model and endpoint rather than turn a laboratory signal into a promised physique result.

Side Effects & Risks

The primary source cannot characterize human adverse-event frequencies for repeated informal use. IGF-related signaling has metabolic and growth effects, so class-related concerns warrant evaluation, but precise rates cannot be borrowed from mecasermin. A clinician needs the actual product, medical history, and other treatments to assess a proposed exposure.

Delivery Options

Route, formulation, and exposure must match before a study can support an administration claim. A claim that proximity to a muscle creates local benefit requires evidence, not simply a plausible story. This entry includes no injection placement, preparation, mixing, or dose-conversion instructions.

Product Quality & Storage

Verify the exact analog and distinguish DES from LR3 and ordinary IGF-1. Chemical identity is necessary but not sufficient: final-product quality and clinical evidence remain separate. A supplier’s research certificate cannot establish patient suitability, efficacy, or lawful availability for the truncated molecule. Storage must follow the authorized finished product’s labeling or an approved study protocol; temperatures and beyond-use times cannot be inferred from research-vial guidance.

Combinations & Interactions

Combining DES with growth hormone, insulin, or other peptides is a separate experiment with additional unknowns. The rat study does not validate a consumer stack or a way to manage its risks. Introducing multiple hormone-active products also makes outcomes and adverse effects more difficult to attribute.

Talking With Your Provider

Bring the underlying health or performance concern to a clinician for assessment and discussion of established options. An educational review can explain what DES research actually shows and why analog identities matter. It does not promise access, a targeted muscle effect, or an appropriate treatment for a healthy person.

Educational purpose only. Not medical advice. Consult licensed provider. Obtain from authorized compounding pharmacies only.

Questions about what you read?
Explore the research library Create a free account
Educational information only. A free account lets you request review of your care goals. This profile does not establish availability, clinical suitability or access to the named compound.

Explore clinically appropriate options with a licensed provider. Inquiry does not guarantee a prescription, research-program acceptance or access to a particular substance.

Questions worth bringing to your appointment.

Are there alternatives that address my goal?
If treatment is appropriate, what monitoring and follow-up would I need?
Could my health history or current medicines change the risks?

Saved discussion topics 0

Save topics you would like to discuss with your healthcare provider. Saving is an expression of interest, not a treatment request or medical recommendation.

Saved only in this browser, on this device—not in a patient account. Other people using this browser may see your list. Clear it when using a shared device. This list is not sent to our team.

Explore your next step with SEINE BIO.

Bring your questions to a wellness consultation. Inclusion in this library does not indicate prescribing or product availability. A consultation does not guarantee a prescription.

Explore consultations Back to Growth-hormone signaling

Educational information · U.S. context · October 7, 2026. No ordering, personalized dosing or injection instructions.

Bring your saved topics to your care team.

Members can select up to five favorites and send a message for review. Your saved list stays in this browser until you choose what to submit.

Choose saved topics for review →